Dimethyl Fumarate

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Dimethyl Fumarate
   1. Pharmacist Assessment Report
   2. Dimethyl Fumarate: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Dimethyl Fumarate: Known uses and market status in Australia

Summary

The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Dimethyl Fumarate, so there is currently no new predicted indication. The drug’s own recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	3
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
multiple sclerosis	licence in another country
psoriasis	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
relapsing-remitting multiple sclerosis

Australia Market Information

Licence	Product	Dosage form	Status
2896K	Tecfidera	Capsule (modified release) 120 mg	Valid

Safety Considerations

• Drug Interactions: 100 potential interactions were identified. The listed examples are all rated Moderate and include:
  • Corticosteroids (hydrocortisone, prednisolone, prednisone, methylprednisolone, dexamethasone, betamethasone, budesonide, triamcinolone)
  • Naltrexone
  • Mercaptopurine
  • Dupilumab
  • Roflumilast
  • Dexrazoxane
  • Radiopharmaceuticals (ibritumomab tiuxetan, iobenguane I-131, tositumomab)
  • Levamisole
  • Trimetrexate
• Literature-derived safety signals: Lymphopenia and the associated risk of progressive multifocal leukoencephalopathy (PML) are documented with DMF (see PMIDs 33091427 and 32808554).

Please refer to the TGA-approved Product Information (PI) for formal warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---